ArticleBMJ open respiratory research2026

Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF.

Toby M Maher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.